```
BM1   MRSEKHLLPLPLLLAICCLGTLHLSSGFPQSVPSYLEGLD
BM2   MRSEKHLLPLPLLLAICCLGTLHLSSGFPQSVPSYLEGLD
BM3   MRSEKHLLPLPLLLAICCLGTLHLSSGFPQSVPSYLEGLD
BM4   MRSEKHLLPLPLLLAICCLGTLHLSSGFPQSVPSYLEGLD
BM5   MRSEKHLLPLPLLLAICCLGTLHLSSGFPQSVPSYLEGLD
BM6   MRSEKHLLPLPLLLAICCLGTLHLSSGFPQSVPSYLEGLD

BM1   IPESERHAFCFSQWTALQDQEQIPSFVMDLCSSIYNRMKV
BM2   IPESE-----------------IPSFVMDLCSSIYNRMKV
BM3   IPESERHAFCFSQWTALQDQEQIPSFVMDLCSSIYNRMKV
BM4   IPESERHAFCFSQWTALQDQEQIPSFVMDLCSSIYNRMKV
BM5   IPESERHAFCFSQWTALQDQEQIPSFVMDLCSSIYNRMKV
BM6   IPESERHAFCFSQWTALQDQEQIPSFVMDLCSSIYNRMKV

BM1   NEENNHEIYKRFLFQFSRAKDPSLKIGESQIATAEYTKRD
BM2   NEENNHEIYKRFLFQFSRAKDPSLKIGESQIATAEYTKRD
BM3   NEENNHEIYKRFLFQFSRAKDPSLKIG------------D
BM4   NEENNHEIYKR----------------ESQIATAEYTKRD
BM5   NE-------------------------ESQIATAEYTKRD
BM6   NE-------------FSRAKDPSLKIGESQIATAEYTKRD

BM1   SSGIVGRPFFLFRPRNGRKVSINEH
BM2   SSGIVGRPFFLFRPRNGRKVSINEH
BM3   SSGIVGRPFFLFRPRNGRKVSINEH
BM4   SSGIVGRPFFLFRPRNGRKVSINEH
BM5   SSGIVGRPFFLFRPRNGRKVSINEH
BM6   SSGIVGRPFFLFRPRNGRKVSINEH
```

Fig. 4. Alignment of full-length translated open-reading frames of NmS precursors generated by splice variation (BM1 through 6) and cloned from a skin secretion library of the toad, *B. maxima*. KR (-Lys-Arg-) indicates propeptide convertase processing sites generating the N-terminals of NmS peptides and GR (-Gly-Arg-) indicates propeptide convertase/amidation enzyme site that generates the C-terminal asparaginamide. Sequences encoded by "spliced out" exons are indicated by hatched lines.

```
BO1   MRSEKHLPPLPLLLAICCLGTLHPSSGFPQSVPSYMEALD
BO2   MRSEKHLPPLPLLLAICCLGTLHPSSGFPQSVPSYMEALD
BO3   MRSEKHLPPLPLLLAICCLGTLHPSSGFPQSVPSYMEALD
BO4   MRSEKHLPPLPLLLAICCLGTLHPSSGFPQSVPSYMEALD
BO5   MRSEKHLPPLPLLLAICCLGTLHPSSGFPQSVPSYMEALD
BO6   MRSEKHLPPLPLLLAICCLGTLHPSSGFPQSVPSYMEALD

BO1   IPESEKLAFCFSQWTALPDQEQIPSFVMDLCSSIYNRMKV
BO2   IPESEKLAFCFSQWTALPDQEQIPSFVMDLCSSIYNRMKV
BO3   IPESEKLAFCFSQWTALPDQEQIPSFVMDLCSSIYNRMKV
BO4   IPESEKLAFCFSQWTALPDQEQIPSFVMDLCSSIYNRMKV
BO5   IPESE-----------------IPSFVMDLCSSIYNRMKV
BO6   IPESEKLAFCFSQWTALPDQEQIPSFVMDLCSSIYNRMKV

BO1   NEENNHEIYKRFLFQFSRTKDPSLKTGESQIATAEYTKRD
BO2   NE---------FLFQFSRTKDPSLKTGESQIATAEYTKRD
BO3   NE-------------------------ESQIATAEYTKRD
BO4   NEENNHEIYKR----------------------------D
BO5   NE-------------------------------------D
BO6   NEENNHEIYKRFLFQFSRTKDPSLKTG------------D

BO1   SSGIVGRPFFLFRPRNGRKVSINEH
BO2   SSGIVGRPFFLFRPRNGRKVSINEH
BO3   SSGIVGRPFFLFRPRNGRKVSINEH
BO4   SSGIVGRPFFLFRPRNGRKVSINEH
BO5   SSGIVGRPFFLFRPRNGRKVSINEH
BO6   SSGIVGRPFFLFRPRNGRKVSINEH
```

Fig. 5. Alignment of full-length translated open-reading frames of NmS precursors generated by splice variation (BO1 through 6) and cloned from a skin secretion library of the toad, *B. orientalis* KR (-Lys-Arg-) indicates propeptide convertase processing sites generating the N-terminals of NmS peptides and GR (-Gly-Arg-) indicates propeptide convertase/amidation enzyme site that generates the C-terminal asparaginamide. Sequences encoded by "spliced out" exons are indicated by hatched lines.

this point. Toad NmS-17 and NmS-33 were obvious cognate ligands for both human receptors with similar orders of potency compared to human NmS, and rat NmS that in turn have been found previously to be comparable to human NmU [20]. Toad NmS-17 was virtually indistinguishable from human NmS in terms of potency at the expressed human FM-4/TGR-1 receptor ($0.231 \pm 0.015$ nM vs. $0.237 \pm 0.027$ nM; $n = 5$, mean ± SEM) whereas it was more potent than human NmS as a ligand for the FM-3/GPR66 receptor ($0.085 \pm 0.005$ nM vs. $0.139 \pm 0.013$ nM).

## Discussion

Neuromedin S has been identified in this study as a new amphibian venom/defensive skin secretion peptide. Reverse phase HPLC fractions of venom from all three species of discoglossid toad from the genus, *Bombina*, which were included in a radioimmunometric screen for bioactive peptides in a sample of 140 species of amphibian, were found to contain peptides that were reactive with an antiserum raised to NmU. *B. maxima* and *B. orientalis* venom fractions contained two immunoreactive peptides, in contrast to that of *B. variegata*, in which a single immunoreactive peptide was detected. Isolation and primary structural analysis of all five NmU-immunoreactive peptides indicated that they exhibited greater structural similarity to the novel neuropeptide, neuromedin S (NmS) [20], than to NmU peptides from the same spectrum of tetrapod vertebrates (Fig. 2).

Neuromedin S (NmS) is a recently discovered neuropeptide in man and rodents which is an obvious structural homolog of NmU that cross-reacts fully with C-terminally directed NmU antisera, interacts with both nominate NmU receptors, and shares biological effects, such as hypertension induction, smooth muscle contraction, and induction of anorexia [20]. However, detailed RT-PCR analysis of NmS distribution revealed that it was mainly expressed in the central nervous system, spleen, and testis [20]. Specifically within the brain, NmS expression was localized predominantly to the core region of the suprachiasmatic nucleus within the hypothalamus—a regulatory center for circadian rhythm that intracerebroventricular administration of NmS was found to shift. This discrete nucleus also expresses mRNA encoding the TGR-1 NmU receptor that was found to be NmS-preferring and thus endogenous NmS may interact with in an autocrine or paracrine manner.

In amphibians, NmU was discovered in the skin secretion of the Australasian White's tree frog (*L. caerulea*) in our laboratory using an approach similar to that adopted in the present study [18]. This peptide, of 23 amino acid residues, was found to be of similar molar potency to porcine NmU-25 in contraction of rat uterine smooth muscle and




Fig. 6. Response curves for toad NmS-17 (filled circle), toad NmS-33 (open circle), human NmS (filled triangle), and rat NmS (open triangle) in the calcium mobilization assay using CHO cells stably expressing FM-3/GPR66 (A) or FM-4/TGR-1 (B) human NmU receptors. The calcium mobilization assay using the FLIPR system has previously been described in detail [20]. Data points represent the means ± SEM of six replicates.

Table 1
Half-maximal response concentrations ($EC_{50}$, in nM) of amphibian and mammalian NmS peptides for effecting calcium mobilization in FM-3/GPR66 or FM-4/TGR-1 stably transfected CHO cell lines

| Peptide | FM-3/GPR66 | FM-4/TGR-1 |
|---|---|---|
| Toad NmS-17 | 0.085 ± 0.005 | 0.231 ± 0.015 |
| Toad NmS-33 | 0.222 ± 0.018 | 0.439 ± 0.020 |
| Human NmS | 0.139 ± 0.013 | 0.237 ± 0.027 |
| Rat NmS | 0.148 ± 0.012 | 0.358 ± 0.021 |

$EC_{50}$ was determined by the FLIPR assay [20], and data were analysed using GraphPad Prism ($n = 6$, mean ± SEM).

of similar affinity to rat NmU in displacing monoradioiodinated rat NmU ligand from rat uterine smooth muscle membranes. Molecular cloning of the frog NmU precursor cDNA from a frog skin library indicated that a series of splice variants were present in addition to the "full-length" open-reading frame transcript judged to be so by alignment with and structural similarities to the homologous human NmU precursor transcript [2]. Interrogation of a fetal human brain cDNA library indicated the same splice variants as discovered in the skin of the amphibian were also generated as a consequence of NmU gene expression in man and that the sites of splice variation occurred precisely at exon/intron boundaries within the human gene that consists of 10 exons [20]. Differential splicing of NmU mRNA is thus a highly conserved phenomenon within the tetrapod vertebrates—a finding that is certainly of biological relevance.

Molecular cloning of NmS cDNAs from libraries constructed using lyophilized venoms of *B. maxima* and *B. orientalis*, using a novel technique developed in our laboratory [19], revealed a series of six transcripts in each species that represented splice variants displaying a striking similarity to those obtained for NmU in amphibian skin and mammalian brain (Figs. 4 and 5). The venom library of *B. variegata* in contrast, apparently contained a single NmS-encoding transcript that represented one of the splice variants present in the other two congeneric species. The reason for this difference is unclear but of note is that *B. variegata* has a geographical distribution (Central Europe) that is different from the other Oriental species. The high degree of phylogenetic conservation in the splice variation observed following expression of the NmU gene in mammals and amphibians can be explained mechanistically by the structure of the human NmU gene that contains 10 exons. The coincident nature of amphibian and human transcripts would imply a very similar if not identical organisation of the amphibian NmU gene. The NmS gene in humans, although exhibiting relatively low nucleotide similarity (53%) with the NmU gene, is likewise composed of 10 exons with comparably conserved exon/intron boundaries. Though no evidence so far exists of differential splicing events occurring in the expression of the human NmS gene, the data presented in this study unequivocally demonstrate that such events occur following expression of the amphibian homolog. As in the case of the NmU gene, these differential splicing events occur predominantly within relatively short exons encoding peptide domains upstream of the NmS-encoding sequence within the precursor protein. Of particular note is the fact that several of these discrete exon-encoded peptide domains terminate in a typical –KR– propeptide convertase processing site such that differential splicing events within this region have the potential to alter the sites of cleavage and hence the nature of the peptide products so generated. This effect explains the presence of the two molecular variants of NmS detected in the venom of two species examined in the present study. NmS-17 was the predominant molecular form of NmS in two species of toad and the only molecular form in the third. This is considerably shorter in chain length than the 33-mers from human and the 36-mers from rat and mouse. Although a 33-mers NmS was isolated from the venom of two of the three species of toads studied, it arises in a different manner in the toads when compared with the human. Fig. 3 shows the alignments of mammalian and amphibian "full-length"

open-reading frames and the typical propeptide convertase processing sites (–KR–) that are indicated. As can be clearly seen, these differ in location between mammalian and amphibian precursors. The –KR– processing site in the amphibian precursors that resides immediately upstream of the NmS-17 encoding domain exhibits a site substitution in the mammalian homologs to –KK–. The specificity of the endogenous propeptide convertases in mammals obviously does not permit cleavage of this motif as no attenuated forms of mammalian NmS were reported in the original publication [20]. The generation of toad NmS-33 occurs as a result of a different process to the 33-mers human homolog. Alternative splicing of exons immediately upstream of the NmS encoding sequence in the amphibian gene (*B. maxima* and *B. orientalis*) results in the generation of a series of putative isomeric precursors. One of these isoforms within each of the two species (BM3 and BO6) encodes NmS-33 as a result of splicing out of an exon that encodes a peptide terminating in the –KR– processing site which generates NmS-17. The N-terminal domain of NmS-33 constitutes the N-terminal domain of the novel 33-mers peptide speculated to exist in the NmU precursor [2] and found to exist as a 34-mers in the human NmS precursor [20]. This novel NmU/NmS gene associated peptide was found to be a potent prolactin-releasing factor when administered intracerebroventricularly in rats [20]. However, intracerebroventricular administration of NmU in rats potently suppresses prolactin release [22]. Thus it would be intriguing to examine the effect of toad NmS-33, a peptide containing both contra-active domains, on prolactin release in this bioassay. While this was beyond the scope of the present study to assess, the ability of both toad NmS-17 and NmS-33 to activate stably transfected NmU receptors in CHO cell lines, as monitored by the generation of transient intracellular calcium fluxes, was studied. Both peptides were found to be equipotent with human NmS and rat NmS in activating both subtypes of NmU receptors, FM-3/GPR66 and FM-4/TGR-1, confirming the previous assertion that NmS peptides are cognate ligands for both of these NmU receptors [20]. Whether NmS or NmU peptides interact with these receptors appears to be determined by the differential spatial distribution of both components of this regulatory system. The fact that both NmU and NmS genes are obviously very closely related in many ways begs the question of their evolutionary origins. In other similar situations in peptide evolutionary biology, it is a general assumption that the degree of phylogenetic conservation of active site residues reflects two things: fundamental physiological importance and perhaps derivation. In Fig. 2, the primary structures of amphibian and mammalian NmS and NmU peptides are compared. Within this comparison that spans the tetrapod vertebrates, NmS displays a fully conserved C-terminal undecapeptide amide whereas a similar set of NmU peptides display a fully conserved pentapeptide amide. The C-terminal amidated region of NmU has been established as the active core with N-terminal extensions having subtle effects on bioactivity in a species-specific manner. This appears to be likewise true for NmS when comparing potencies of rat/mouse NmS-36 with toad NmS-17. In view of this evidence, we would contend that the original gene encoded NmS and that the gene duplication event that gave rise to NmU must have preceded tetrapod vertebrate evolution as both are separate entities in amphibians. Thus the results of this study have provided important insights into regulatory peptide biology and have posed several fundamental questions that will form the basis of further in-depth investigations to dissect the relative roles of NmS and NmU peptides in regulation of important physiological events such as control of feeding behavior and circadian rhythm modulation.

## Acknowledgments

Mei Zhou is in receipt of an Overseas Postgraduate Studentship from Queen's University, Belfast. This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

## References

[1] N. Minamino, K. Kangawa, H. Matsuo, Neuromedin U-8 and U-25: Novel uterus stimulating and hypertensive peptides identified in porcine spinal cord, Biochem. Biophys. Res. Commun. 130 (1985) 1078–1085.
[2] C. Austin, G. Lo, K.A. Nandha, L. Meleagros, S.R. Bloom, Cloning and characterization of the cDNA encoding the human neuromedin U (NmU) precursor: NmU expression in the human gastrointestinal tract, J. Mol. Endocrinol. 14 (1995) 157–169.
[3] F. O'Harte, C.S. Bockman, P.W. Abel, J.M. Conlon, Isolation, structural characterization and pharmacological activity of dog neuromedin U, Peptides 12 (1991) 11–15.
[4] J.M. Conlon, J. Domin, L. Thim, V. DiMarzo, H.R. Moris, S.R. Bloom, Primary structure of neuromedin U from the rat, J. Neurochem. 51 (1988) 988–991.
[5] N. Minamino, K. Kangawa, M. Honzawa, H. Matsuo, Isolation and structural determination of rat neuromedin U, Biochem. Biophys. Res. Commun. 156 (1988) 355–360.
[6] R. Murphy, C.A. Turner, J.B. Furness, L. Parker, A. Giraud, Isolation and microsequence analysis of a novel form of neuromedin U from guinea pig small intestine, Peptides 11 (1990) 613–617.
[7] R. Kage, F. O'Harte, L. Thim, J.M. Conlon, Rabbit neuromedin U-25: lack of conservation of a posttranslational processing site, Regul. Pept. 33 (1991) 191–198.
[8] J. Domin, M.A. Benito-Orfila, K.A. Nandha, A. Aitken, S.R. Bloom, The purification and sequence analysis of an avian neuromedin U, Regul. Pept. 41 (1992) 1–8.
[9] J. Domin, Y. Yiangou, R.A. Spokes, A. Aitken, K.B. Parmar, B.J. Chrysanthou, S.R. Bloom, The distribution, purification, and pharmacological action of an amphibian neuromedin U, J. Biol. Chem. 264 (1989) 20881–20885.
[10] D.R. Brown, F.L. Quito, Neuromedin U octapeptide alters ion transport in porcine jejunum, Eur. J. Pharmacol. 155 (1988) 159–162.
[11] L.K. Malendowicz, Role of neuromedins in the regulation of adrenocortical function, Horm. Metab. Res. 30 (1998) 374–383.
[12] S. Sumi, K. Inoue, M. Kogire, R. Doi, K. Takaori, T. Suzuki, H. Yajima, T. Tobe, Effect of synthetic neuromedin U-8 and U-25, novel peptides identified in porcine spinal cord, on splanchnic circulation in dogs, Life Sci. 41 (1987) 1585–1590.

[13] M. Nakazoto, R. Hanada, N. Murakami, Y. Date, M.S. Mondal, M. Kojima, H. Yoshimatsu, K. Kangawa, S. Matsukura, Central effects of Neuromedin U in the regulation of energy homeostasis, Biochem. Biophys. Res. Commun. 277 (2000) 191–194.

[14] R. Hanada, H. Teranishi, J.T. Pearson, M. Kurokawa, H. Hosoda, N. Fukushima, Y. Fukue, R. Serino, H. Fujihara, Y. Ueta, M. Ikawa, M. Okabe, N. Murakami, M. Shirai, H. Yoshimatsu, K. Kangawa, M. Kojima, Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway, Nat. Med. 10 (2004) 1067–1073.

[15] R. Hanada, M. Nakazoto, N. Murakami, S. Sakihara, H. Yoshimatsu, K. Toshinai, T. Hanada, T. Suda, K. Kangawa, S. Matsukura, T. Sakata, A role for neuromedin U in stress response, Biochem. Biophys. Res. Commun. 289 (2001) 225–228.

[16] V. Erspamer, P. Melchiorri, G.F. Falconieri-Erspamer, P.P. Montecucchi, R. De Castiglione, Phyllomedusa skin: a huge factory and store-house of a variety of active peptides, Peptides 3 (1985) 7–12.

[17] L.H. Lazarus, M. Atilla, The toad, ugly and venomous, wears yet a precious jewel in his skin, Prog. Neurobiol. 41 (1993) 473–507.

[18] A.L. Salmon, A.H. Johnsen, M. Bienert, G. McMurray, K.A. Nandha, S.R. Bloom, C. Shaw, Isolation, structural characterization, and bioactivity of a novel neuromedin U analog from the defensive skin secretion of the Australasian tree frog, *Litoria caerulea*, J. Biol. Chem. 275 (2000) 4549–4554.

[19] T. Chen, S. Farragher, A.J. Bjourson, D.F. Orr, P. Rao, C. Shaw, Granular gland transcriptomes in stimulated amphibian skin secretions, Biochem. J. 371 (2003) 125–130.

[20] K. Mori, M. Miyazato, T. Ida, N. Murakami, R. Serino, Y. Ueta, M. Kojima, K. Kangawa, Identification of neuromedin S and its possible role in the mammalian circadian oscillator system, EMBO J. 24 (2005) 325–335.

[21] M.J. Tyler, D.J.M. Stone, J.H. Bowie, A novel method for the release and collection of dermal, glandular secretions from the skin of frogs, J. Pharmacol. Toxicol. Meth. 28 (1992) 199–200.

[22] J. Gartlon, P. Szekeres, M. Pullen, H.M. Sarau, N. Aiyar, U. Shabon, D. Michalovich, K. Steplewski, C. Ellis, N. Elshourbagy, M. Duxon, T.E. Ashmeade, D.C. Harrison, P. Murdock, S. Wilson, A. Ennaceur, A. Atkins, C. Heidbreder, J.J. Hagan, A.J. Hunter, D.N.C. Jones, Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats, Psychopharmacology (Berlin) 117 (2004) 1–14.

0013-7227/06/$15.00/0
*Printed in U.S.A.*

Endocrinology 147(5):2306–2314
Copyright © 2006 by The Endocrine Society
doi: 10.1210/en.2005-1357

# Des-Acyl Ghrelin Induces Food Intake by a Mechanism Independent of the Growth Hormone Secretagogue Receptor

Koji Toshinai, Hideki Yamaguchi, Yuxiang Sun, Roy G. Smith, Akihiro Yamanaka, Takeshi Sakurai, Yukari Date, Muhtashan S. Mondal, Takuya Shimbara, Takashi Kawagoe, Noboru Murakami, Mikiya Miyazato, Kenji Kangawa, and Masamitsu Nakazato

*Department of Internal Medicine (K.T., H.Y., Y.D., M.S.M., T.SH., T.K., M.N.), Miyazaki Medical College, University of Miyazaki, Miyazaki 889-1692, Japan; Department of Veterinary Physiology (N.M.), University of Miyazaki, Miyazaki 889-2151, Japan; Huffington Center on Aging (Y.S., R.G.S.), Baylor College of Medicine, Texas 77030; Department of Pharmacology (A.Y., T.SA.), University of Tsukuba, Ibaraki 305-8575, Japan; and National Cardiovascular Center Research Institute (M.M., K.K.), Osaka 565-8565, Japan*

**Ghrelin, an acylated peptide produced predominantly in the stomach, stimulates feeding and GH secretion via interactions with the GH secretagogue type 1a receptor (GHS-R1a), the functionally active form of the GHS-R. Ghrelin molecules exist in the stomach and hypothalamus as two major endogenous forms, a form acylated at serine 3 (ghrelin) and a des-acylated form (des-acyl ghrelin). Acylation is indispensable for the binding of ghrelin to the GHS-R1a. Ghrelin enhances feeding via the neuronal pathways of neuropeptide Y and orexin, which act as orexigenic peptides in the hypothalamus. We here studied the effect of des-acyl ghrelin on feeding behavior. Intracerebroventricular (icv) administration of rat des-acyl ghrelin to rats or mice fed *ad libitum* stimulated feeding during the light phase; neither ip nor icv administration of des-acyl ghrelin to fasting mice suppressed feeding. The icv administration of des-acyl ghrelin induced the expression of Fos, a marker of neuronal activation, in orexin-expressing neurons of the lateral hypothalamic area, but not neuropeptide Y-expressing neurons of the arcuate nucleus. Peripheral administration of des-acyl ghrelin to rats or mice did not affect feeding. Although icv administration of ghrelin did not induce food intake in GHS-R-deficient mice, it did in orexin-deficient mice. In contrast, icv administration of des-acyl ghrelin stimulated feeding in GHS-R-deficient mice, but not orexin-deficient mice. Des-acyl ghrelin increased the intracellular calcium concentrations in isolated orexin neurons. Central des-acyl ghrelin may activate orexin-expressing neurons, perhaps functioning in feeding regulation through interactions with a target protein distinct from the GHS-R. (*Endocrinology* 147: 2306–2314, 2006)**

GHRELIN IS A 28-amino-acid peptide isolated from human and rat stomach as an endogenous ligand for the GH secretagogue receptor (GHS-R) (1). The GHS-R, a G protein-coupled seven-transmembrane domain receptor, was initially identified as a receptor for small synthetic molecules termed GH secretagogues (GHSs), such as L-692,429, GHRP-6, and MK-0677, all of which act on the pituitary to stimulate GH secretion (2, 3). Two GHS-R subtypes are generated by alternative splicing of a single gene: the full-length type 1a receptor (GHS-R1a) and a carboxyl-terminally truncated form, the GHS-R type 1b (GHS-R1b), that encodes a protein containing transmembrane domain one to five (2, 3). The GHS-R1a is the functionally active, signal transducing form of the GHS-R, whereas the GHS-R1b is devoid of high-affinity ligand binding and signal transduction activity. Ghrelin molecules, predominantly produced by endocrine cells of the gastric oxyntic glands (4, 5), exist in two major molecular forms, ghrelin and des-*n*-octanoyl ghrelin (des-acyl ghrelin) (6). These two ghrelin molecules are also produced in the rat hypothalamus, as demonstrated by the combination of reverse-phase HPLC (RP-HPLC) with two separate RIAs recognizing ghrelin and des-acyl ghrelin (7, 8). All ghrelin species identified in fish, amphibians, birds, and many mammals possess a unique structural modification of the hydroxyl group of their third residue, which is either serine or threonine, by *n*-octanoic acid (9). This acylation is essential for the binding of ghrelin to the GHS-R1a (1, 10, 11); thus, the acylated form has been designated as ghrelin in our original description (1). Administration of ghrelin stimulates food intake in humans and rats (12–16) but does not change feeding behavior in GHS-R-deficient mice (17), suggesting that ghrelin enhances food intake via GHS-R-mediated signaling.

Several recent *in vitro* studies have demonstrated that radiolabeled ghrelin and des-acyl ghrelin bound to the membranes of PC-3 prostate tumor cells, H9c2 cadiomyocytes and isolated adipocytes, none of which expressed the GHS-R (18–20). This binding could be displaced by ghrelin, des-acyl ghrelin, and synthetic GHSs. Ghrelin and des-acyl ghrelin exhibit similar GHS-R-independent biological activities, including a cytoprotective effect on cultured cardiomyocytes

**First Published Online February 16, 2006**

Abbreviations: AgRP, Agouti gene-related protein; CRF, corticotropin-releasing factor; 2-DG, 2-deoxy-D-glucose; GHS, GH secretagogue; GHS-R, GH secretagogue receptor; HKRB, Krebs-Ringer bicarbonate buffer; icv, intracerebroventricular(ly); LHA, lateral hypothalamic area; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; PVN, paraventricular nucleus; RP-HPLC, reverse-phase HPLC.

***Endocrinology* is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.**

(18), the inhibition of cell proliferation of breast carcinoma cell lines (19), the reduction of glycerol release from rat epididymal adipocytes (20), an ionotropic effect on guinea pig papillary muscle (21), and the promotion of bone marrow adipogenesis (22). Although the signaling molecules downstream of des-acyl ghrelin remain undefined, des-acyl ghrelin appears to share a subset of biological activities with ghrelin in peripheral tissues through an unidentified receptor or a target protein unique from the GHS-R.

The coordination of the regulation of food intake and energy expenditure occurs in the hypothalamus. Glucoprivic states induced by fasting or treatment with 2-deoxy-D-glucose (2-DG), a selective inhibitor of carbohydrate metabolism, increase feeding through the activation of orexigenic peptides, neuropeptide Y (NPY) and agouti gene-related protein (AgRP) in the arcuate nucleus (23). Secretion of des-acyl ghrelin from the rat hypothalamus increased in glucoprivic states induced by fasting or treatment with 2-DG (7). The axonal terminals of neurons that produce ghrelin and des-acyl ghrelin make direct synaptic contacts with NPY- and orexin-expressing neurons, which participate in hypothalamic feeding regulation (16, 24). Both ghrelin and des-acyl ghrelin may have a direct central action on the control of feeding.

We here investigated the effect of central or peripheral administration of des-acyl ghrelin on food intake in rats and mice and Fos expression, a marker of neuronal activation (25), in neurons that produce the orexigenic hypothalamic peptides, NPY/AgRP, orexin, or melanin-concentrating hormone (MCH). We studied the functional signaling downstream of des-acyl ghrelin using orexin-deficient mice and rats pretreated with antiorexin-A and -B IgGs. We confirmed that des-acyl ghrelin increased the intracellular calcium concentrations in orexin neurons dispersed from the lateral hypothalamic area (LHA) by the calcium-imaging analysis. We demonstrated that des-acyl ghrelin increased feeding by activation of orexin neurons in the LHA. We examined whether des-acyl ghrelin-induced food intake was mediated by the GHS-R pathway using GHS-R-deficient mice. Des-acyl ghrelin appears to regulate feeding via a receptor or target protein independent of the GHS-R.

## Materials and Methods

### *Animals*

We used male Wistar rats (Charles River Japan, Inc., Shiga, Japan), weighing 300–350 g, male C57BL/6 (Charles River Japan, Inc.), weighing 24–28 g, and male ddy mice (Kiwa Laboratory Animals Co., Ltd., Wakayama, Japan), weighing 35–39 g. Orexin-deficient mice (12-wk-old, male) and GHS-R-deficient mice (12-wk-old, male) were generated by targeted mutation of embryonic stem cells as reported (17, 26). All animals were individually housed in plastic cages at a constant room temperature in a 12-h light (0800–2000 h)/12-h dark cycle and given standard laboratory chow and water *ad libitum*. All procedures were approved by University of Miyazaki Animal Care and Use Committee and were in accordance with the Japanese Physiological Society's guidelines for animal care. Anesthesia was given as an ip injection of sodium pentobarbital (Abbot Labs., Chicago, IL). Intracerebroventricular (icv) cannulae were implanted into the lateral cerebral ventricles of rats and mice. Proper placement of the cannulae was verified at the end of the experiment by dye administration. Intravenous cannulae were implanted into the rat right jugular vein. Only animals that exhibited progressive weight gain after surgery were used.

### *Peptide synthesis*

Rat ghrelin and des-acyl ghrelin were purchased from Peptide Institute, Inc. (Osaka, Japan). Adequate purification of synthesized peptides was ascertained by RP-HPLC, ion-exchange-HPLC, capillary zone electrophoresis, amino acid sequencing, and mass spectrometry (MALDI-MS). Ghrelin and des-acyl ghrelin were separately eluted, each as single peaks by RP-HPLC performed using a TSK ODS SIL 120A column (4.6 × 150 mm) (Tosho Co., Tokyo, Japan) with a linear gradient of 10–60% acetonitrile ($CH_3CN$) containing 0.1% trifluoroacetic acid (Fig. 1).

### *Fos expression*

Ghrelin (200 pmol/10 μl saline), des-acyl ghrelin (200 pmol/10 μl saline), or saline was injected icv into Wistar rats or GHS-R-deficient mice 90 min before transcardial perfusion with fixative containing 4% paraformaldehyde. The brain was sectioned into 20- or 40-μm-thick samples. Fos-specific immunohistochemistry was performed as described (27). Hypothalamic sections from rats and GHS-R-deficient mice were incubated for 2 d with goat anti-Fos antiserum (Santa Cruz Biotechnology, Santa Cruz, CA; dilution 1:1500), then stained using the avidin-biotin complex method (Vectastain Elite ABC kit; Vector Laboratories, Inc., Burlingame, CA). These sections were also stained with either rabbit antiorexin-A (dilution 1:3000) (16, 27) or rabbit anti-MCH (Phoenix Pharmaceuticals, Inc., Belmont, CA; dilution 1:200) antisera. We observed orexin- and MCH-expressing neurons by light microscopy. For immunofluorescence microscopy, we incubated hypothalamic sections of GHS-R-deficient mice with goat anti-Fos antiserum (dilution 1:1500) for 2 d at 4 C, then performed an additional 2 h incubation with




FIG. 1. RP-HPLC analysis of synthetic rat ghrelin (A) and des-acyl ghrelin (B) used for experimentation. Each peptide (0.3 nmol) was loaded onto a TSK ODS SIL 120A column using a linear gradient of 10–60% $CH_3CN$ containing 0.1% trifluoroacetic acid at a rate of 1.0 ml/min for 40 min. Each peptide is eluted as a single peak whose elution position was identical with that of the corresponding synthetic peptide.

Alexa 488-conjugated donkey antigoat IgG antibody (Molecular Probes, Inc., Eugene, OR; dilution 1:400). After washing with PBS (pH 7.4), samples were incubated with a rabbit antiorexin-A antiserum for 2 d at 4 C and Alexa 546-labeled goat antirabbit IgG antibody (Molecular Probes; dilution 1:400) for a final 2 h. Slides were observed on a fluorescence microscope (BH2-RFC; Olympus, Tokyo, Japan).

### *Food intake*

Experiments were performed 1 wk after the implantation of icv or iv cannulae. First, ghrelin or des-acyl ghrelin (each at 200 pmol/10 $\mu$l saline) was administered icv at 1000 h to rats fed *ad libitum* (n = 10 per group). The 1-, 2-, and 4-h food intake amounts were then measured. Second, des-acyl ghrelin (1 nmol/10 $\mu$l saline) was administered icv to rats (n = 6 per group) 10 min before the beginning of the dark phase, after which the 30-min food intake was measured. Third, ghrelin (1.5 nmol) or des-acyl ghrelin (1.5 or 5 nmol/100 $\mu$l saline) was administered iv to rats at 1000 h through an iv cannula. Fourth, des-acyl ghrelin (1 or 5 nmol/2 $\mu$l saline) was administered ip at 1000 h to C57BL/6 mice fed *ad libitum* (n = 8 per group). Fifth, 3 h after an icv administration of antiorexin-A and -B (each at 0.25 $\mu$g/2.5 $\mu$l saline), anti-NPY (0.5 $\mu$g/5 $\mu$l saline), or normal rabbit serum (0.5 $\mu$g/5 $\mu$l saline) IgGs, ghrelin or des-acyl ghrelin (each at 200 pmol/5 $\mu$l saline) was administered at 1200 h to rats (n = 10–12 per group). Sixth, ghrelin or des-acyl ghrelin (each at 200 pmol/2 $\mu$l saline) was administered icv at 1000 h to orexin-deficient mice or their wild-type littermates (n = 6–8 per group). Seventh, ghrelin (200 pmol/2 $\mu$l saline), des-acyl ghrelin (200 pmol/2 $\mu$l saline) or NPY (1 nmol/2 $\mu$l saline; Peptide Institute, Inc.) was administered icv at 1000 h to GHS-R-deficient mice or their wild-type littermates (n = 6–8 per group). With the exception of the first and second experiments, 2-h food intake was measured in all tests. Eighth, ghrelin or des-acyl ghrelin (each at 1 nmol/2 $\mu$l saline) was administered icv at 1000 h to ddy mice fed *ad libitum*. Ninth, des-acyl ghrelin (1 nmol/2 $\mu$l saline) was administered icv at 1000 h to ddy mice that had fasted for the previous 16 h (n = 8 per group). Tenth, des-acyl ghrelin (1 nmol/50 $\mu$l saline) was administered ip at 1000 h to ddy mice that had fasted for the previous 16 h (n = 8 per group). After the injections of ddy mice in the eighth, ninth, and tenth experiments outlined above, we measured 20-min, 1-h, and 2-h food intake. These feeding tests were performed using a cross-over design experiments in which animals were randomized to receive either test substance with a washout period of 3 d between each administration.

### *Measurement of cytosolic $Ca^{2+}$ concentration ($[Ca^{2+}]i$)*

The LHA of rat brain was punched out according to the *Atlas of the Rat Brain* (28). The tissue was washed twice with HEPES and Krebs-Ringer bicarbonate buffer (HKRB) [129 mM NaCl, 5.0 mM $NaHCO_3$, 4.7 mM KCl, 1.2 mM $KH_2PO_4$, 1.8 mM $CaCl_2$, 1.2 mM $MgSO_4$, and 10 mM HEPES (pH 7.4)] containing 10 mM glucose. The LHA was incubated in HKRB supplemented with 1 mg/ml papain (Sigma-Aldrich, St. Louis, MO), 5 mg/ml deoxyribonuclease, and 0.025% BSA for 20 min at 36 C in a shaking water bath, then LHA cells were dispersed by mechanical desegregation for 4 min. The cell suspension was diluted with HKRB and centrifuged at 100 × *g* for 5 min. The pellet was resuspended in HKRB and distributed onto the glass well (Nunc 96 Microwell Optical Bottom Plate; Nalge Nunc International, Rochester, NY). Measurement of $[Ca^{2+}]i$ was carried out 2–4 h after the preparation of cells. The cells were loaded with Fluo-3 for 20 min in HEPES buffer solution [10 mM HEPES, 140 mM NaCl, 5.0 mM KCl, 1.2 mM $MgCl_2$, 2.0 mM $CaCl_2$, 10 mM glucose, and 2 $\mu$m Fluo-3/acetoxymethylester (Dojindo Labs, Kumamoto, Japan) (pH 7.2)]. They were washed twice with HEPES buffer, then filled with 100 $\mu$l HEPES buffer. One min after, 50 $\mu$l of 3 $\mu$M rat des-acyl ghrelin were added into the well. $[Ca^{2+}]i$ was determined by measuring fluorescence signal from the $Ca^{2+}$ indicator Fluo-3/acetoxymethylester, with 480 nm excitation and 530 nm emission using a cooled charge-coupled device camera, and the ratio image was produced in Functional Imaging Cell-Sorting System (IMACS; Hamamatsu Photonics, Hamamatsu, Japan). The level of $[Ca^{2+}]i$ in a single neuron was recorded for 6 min after the administration of des-acyl ghrelin. After $[Ca^{2+}]i$ measurement, the neurons were fixed with 4% paraformaldehyde overnight. They were incubated with rabbit antiorexin-A antiserum (dilution 1:1500) for 2 d at 4 C, then Alexa 350-conjugated goat antirabbit IgG antibody (dilution 1:400) for 2 h (16, 27). The picture of calcium imaging was collated with the immunohistochemical picture. Fluorescence signals from Fluo-3 were converted automatically to pseudo colors in IMACS. The levels of $[Ca^{2+}]i$ were assigned pseudo colors ranging from blue of the lowest value through yellow to red of the highest value. Fluorescence signals from Alexa-350 were shown in white.

### *Measurement of locomotor activity*

Locomotor activity of rats was measured using a rat locomotor activity recording system (Muromachi Co. Ltd., Tokyo, Japan) comprising infrared sensors, an interface and a computer. The infrared sensors were placed above the cages and measured all locomotor activity. A cage with the infrared sensor was placed in an isolated chamber with a controlled light/dark cycle. Rats were given icv des-acyl ghrelin (1 nmol/10 $\mu$l saline), human orexin-A (Peptide Institute, Inc.; 1 nmol/10 $\mu$l saline) or saline administration icv at 0900 h (n = 5 per group), then these rats were immediately returned to their individual cages. Locomotor activity counts were made 30 min and analyzed by Compact ACTAM Software (Muromachi Co. Ltd.).

### *GH response*

Ghrelin or des-acyl ghrelin (each at 1.5 nmol/100 $\mu$l) was administered iv to rats (n = 6 per group) at 1000 h. Blood samples (80 $\mu$l) were obtained from the tail veins at 0, 15, 30, and 60 min after administration. After removal, six anterior pituitary glands of rats were immersed in Hanks' balanced salt solution, then incubated at 37 C for 30 min. Each one pituitary grand was placed in a polystyrene well (16 mm in diameter; Iwaki Glassware Co., Tokyo, Japan) filled with oxygenated medium (DMEM containing 2.5% fetal calf serum and 2.5% bovine serum). After rinsing twice in 500 $\mu$l medium for 1 min each, 750 $\mu$l medium was added into each well for 5 min. The medium was then collected into plastic microtubes to evaluate basal GH secretion. The pituitary glands were then stimulated for 5 min with medium containing either ghrelin or des-acyl ghrelin (1 $\mu$M). The medium was collected into plastic microtubes to quantify GH concentration with a Biotrak Rat GH RIA kit




FIG. 2. Effect of ghrelin or des-acyl ghrelin on food intake in rats. A, Intracerebroventricular administration of des-acyl ghrelin or ghrelin (each at 200 pmol) at 1000 h. *, $P < 0.001$ *vs.* saline; #, $P < 0.05$; ##, $P < 0.001$ *vs.* ghrelin; §, $P < 0.001$ *vs.* 1-h food intake. B, Intravenous administration of ghrelin (1.5 nmol) or des-acyl ghrelin (1.5 or 5 nmol) at 1000 h. *, $P < 0.001$ *vs.* saline; #, $P < 0.001$ *vs.* ghrelin.




FIG. 3. Fos expression in the hypothalamus after icv administration of ghrelin or des-acyl ghrelin (each at 200 pmol). A, Fos expression (*dark blue-black*) in the LHA and arcuate nucleus of rats given ghrelin. B, Costaining (*arrows*) of Fos (*dark blue-black*) and orexin (*brown*) in rats given ghrelin. The *inset* is a higher magnification of Fos expression in an orexin-expressing neuron. C, No Fos (*dark blue-black*) expression in MCH-expressing neurons (*brown*) after ghrelin administration. D, Fos expression (*dark blue-black*) in the hypothalamus of rats given des-acyl ghrelin. E, Fos expression (*dark blue-black*) in the LHA of rats given des-acyl ghrelin. No Fos (*dark blue-black*) expression in the arcuate nucleus (F) or the PVN (G) after des-acyl ghrelin administration. H, Costaining (*arrows*) of Fos (*dark blue-black*) and orexin (*brown*) in rats given des-acyl ghrelin. The *inset* is a higher magnification of Fos expression in an orexin-expressing neuron. I, No expression of Fos (*dark blue-black*) is observed in MCH-expressing neurons (*brown*) after des-acyl ghrelin administration. J, Fos expression (*dark blue-black*) in the LHA of GHS-R-deficient mice given des-acyl ghrelin. K, No Fos expression (*brown*) in the arcuate nucleus of GHS-R-deficient mice given des-acyl ghrelin. L, Costaining of Fos (*green*) and orexin (*red*) in the LHA neurons of GHS-R-deficient mice given des-acyl ghrelin. 3V, Third ventricle; Arc, arcuate nucleus; f, fornix. *Scale bars*, A, D, 200 μm; B, C, E, F, H, G, H, I, J, K, L, 50 μm.

(Amersham, Buckinghamshire, UK). The experiment was concluded by treatment with 60 mM KCl to induce depolarization.

### *Statistic analysis*

Data (mean ± SEM) were analyzed by ANOVA and the *post hoc* Scheffé's F test. Differences were considered to be significant when the $P$ values were less than 0.05.

## Results

### *Des-acyl ghrelin-induced food intake*

The icv administration of either ghrelin or des-acyl ghrelin to rats stimulated food intake (Fig. 2A). Although ghrelin increased food intake for at least 2 h after administration, the effect of des-acyl ghrelin lasted for only 1 h. Des-acyl ghrelin also significantly increased the early dark-phase food intake in rats in comparison to saline administration (des-acyl ghrelin, 2.04 ± 0.37 g/30 min; saline, 0.96 ± 0.23 g/30 min, $P < 0.05$). Next, we studied the effect of peripherally administered des-acyl ghrelin on feeding. A single iv administration of ghrelin significantly increased feeding, whereas des-acyl ghrelin did not (Fig. 2B). An ip administration of des-acyl ghrelin to C57BL/6 mice fed *ad libitum* did not increase food intake (des-acyl ghrelin 1 nmol, 0.05 ± 0.03 g/2 h; 5 nmol, 0.04 ± 0.02 g/2 h; saline, 0.05 ± 0.02 g/2 h).

*Fos expression*

Intracerebroventricular administration of ghrelin induced Fos expression in the LHA and arcuate nucleus (Fig. 3A). In contrast, icv administration of des-acyl ghrelin induced Fos in the LHA, but not the arcuate nucleus or the paraventricular nucleus (PVN) (Fig. 3, D–G). By double immunohistochemistry, ghrelin induced Fos in 32 ± 7% of orexin-immunoreactive neurons (Fig. 3B). Des-acyl ghrelin induced Fos in 22 ± 5% of orexin-immunoreactive neurons (Fig. 3H). In the LHA, neither ghrelin nor des-acyl ghrelin induced Fos in MCH-immunoreactive neurons (Fig. 3, C and I). Intracerebroventricular administration of des-acyl ghrelin to GHS-R-deficient mice induced Fos in the LHA, but not the arcuate nucleus (Fig. 3, J and K). In GHS-R-deficient mice, des-acyl ghrelin induced Fos expression in 28 ± 2% of orexin-immunoreactive neurons, whereas ghrelin did not induce the expression of Fos in any hypothalamic neurons (Fig. 3L).

*Functional relationship between des-acyl ghrelin and orexin in feeding*

We examined the effects of orexin and NPY blockades on des-acyl ghrelin-induced food intake. Both ghrelin and des-acyl ghrelin increased food intake in rats given an icv administration of control IgG (Fig. 4). Pretreatment with anti-orexin-A and -B IgGs, however, reduced ghrelin-induced food intake by 29% from the amounts seen in rats given control IgG and ghrelin, whereas pretreatment with anti-orexin-A and -B IgGs completely abolished des-acyl ghrelin-induced food intake. Whereas pretreatment with anti-NPY IgG reduced ghrelin-induced feeding in rats in comparison to rats given control IgG and ghrelin, anti-NPY IgG did not affect des-acyl ghrelin-induced feeding in comparison to rats given control IgG and des-acyl ghrelin (Fig. 4).

Orexin-deficient mice were used to verify the functional relationship between des-acyl ghrelin and orexin in feeding regulation. Although ghrelin induced food intake in orexin-deficient mice, the potency of this induction in these mice was significantly reduced from that seen in wild-type littermates (Fig. 5A). Des-acyl ghrelin stimulated feeding in wild-type mice, but not in orexin-deficient mice (Fig. 5A). To investigate whether des-acyl ghrelin regulates feeding through the GHS-R, we gave an icv administration of des-acyl ghrelin to GHS-R-deficient mice. Des-acyl ghrelin, but not ghrelin, stimulated feeding in GHS-R-deficient mice (Fig. 5B). Des-acyl ghrelin-induced feeding in GHS-R-deficient mice was more potent than that induced in wild-type littermates. NPY was used as a positive control to evaluate the orexigenic effects on GHS-R-deficient mice. NPY-induced food intake was similar in both GHS-R-deficient mice and their wild-type littermates (Fig. 5B).




FIG. 4. The effect of antiorexin-A and -B (each at 0.25 μg) and anti-NPY (0.5 μg) IgGs on ghrelin- or des-acyl ghrelin-induced feeding. Ghrelin or des-acyl ghrelin (each at 200 pmol) was given to rats 3 h after icv administration of IgG. The 2-h food intake was then measured. NRS, Normal rabbit serum. *, $P < 0.01$ *vs.* ghrelin; #, $P < 0.05$; ##, $P < 0.01$ *vs.* NRS IgG.




FIG. 5. A, Effect of icv administration of ghrelin or des-acyl ghrelin (each at 200 pmol) on 2-h food intake in orexin-deficient mice. *, $P < 0.05$, **; $P < 0.01$ *vs.* saline; #, $P < 0.05$; ##, $P < 0.01$ *vs.* ghrelin, §, $P < 0.05$, §§, $P < 0.01$ *vs.* wild-type mice. B, Effect of icv administration of ghrelin (200 pmol), des-acyl ghrelin (200 pmol), or NPY (1 nmol) on 2-h food intake in GHS-R-deficient mice. *, $P < 0.05$; **, $P < 0.001$ *vs.* saline; #, $P < 0.001$ *vs.* ghrelin; §, $P < 0.05$; §§, $P < 0.01$ *vs.* wild-type mice.

Intracerebroventricular administration of des-acyl ghrelin increased food intake in ddy mice fed *ad libitum* (Fig. 6A). Neither icv nor ip administration of des-acyl ghrelin suppressed food intake in ddy mice that had fasted for 16 h (Fig. 6, B and C).

*Cytosolic $[Ca^{2+}]i$ response in orexin neurons*

We studied the cytosolic $[Ca^{2+}]i$ response of orexin-expressing neurons to des-acyl ghrelin. Some cells dispersed from the rat LHA showed increased cytosolic $[Ca^{2+}]i$ in response to des-acyl ghrelin administration (Fig. 7, A and B). These cells showed orexin immunoreactivity by immunohistochemistry (Fig. 7C).

*Locomotor activity*

We examined the effect of des-acyl ghrelin on locomotor activity. Intracerebroventricular administration of des-acyl




FIG. 6. Effect of des-acyl ghrelin on food intake in ddy mice. A, Intracerebroventricular administration of ghrelin or des-acyl ghrelin (each at 1 nmol) at 1000 h to mice *ad libitum*. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ *vs.* saline; #, $P < 0.01$ *vs.* ghrelin. Neither icv (B) nor ip (C) administration of des-acyl ghrelin (1 nmol) suppressed feeding in mice that had fasted for 16 h.

ghrelin to rats significantly increased locomotor activity compared with saline administration (Fig. 8). Orexin-A also significantly increased locomotor activity in these rats.




FIG. 7. Effect of des-acyl ghrelin on $[Ca^{2+}]i$ response in isolated orexin-expressing neurons. A, A picture shows the basal level of $[Ca^{2+}]i$ in neurons (*blue*) before administration of des-acyl ghrelin. B, Des-acyl ghrelin increased cytosolic $[Ca^{2+}]i$ in two neurons (*arrows*). C, Immunostaining of orexin-expressing neurons (*white*) after the measurement of $[Ca^{2+}]i$ response.




FIG. 8. Effects of icv administration of des-acyl ghrelin or orexin-A (each at 1 nmol) on locomotor activity in rats. *, $P < 0.05$ *vs.* saline.

### *GH response*

We studied the release of GH in response to peripheral des-acyl ghrelin administration. Intravenous administration of ghrelin elicited a marked increase in plasma GH levels, with the peak occurring 15 min after administration (Fig. 9A). Intravenous administration of des-acyl ghrelin did not stimulate GH release. We examined the effect of des-acyl ghrelin on GH release from isolated samples of the rat anterior pituitary. GH concentrations in the culture medium of the anterior pituitary cultures increased in response to ghrelin administration, but not to des-acyl ghrelin administration (Fig. 9B).

## Discussion

At present, the amino acid sequences of ghrelin peptides in 21 species of fish, amphibians, birds, and mammals have been determined (9). All of the ghrelin molecules identified possess a serine or threonine as the third amino acid residue. A hydroxyl group of this amino acid forms an ester with a monocarboxylic acid of medium-chain fatty acid (6). Ghrelin peptide is present in the stomach of humans, rats, and mice as two major molecular forms: ghrelin and des-acyl ghrelin (6). In the plasma, ghrelin accounts for only 2–20% of total ghrelin immunoreactivity (6, 7, 28–30). This is likely due to the shorter half-life of ghrelin than that of des-acyl ghrelin because plasma ghrelin rapidly disappears from the circulation because of binding to the GHS-R in the systemic tissues (31). Deacylation of ghrelin to des-acyl ghrelin, which rapidly occurs in the plasma, is also responsible for the reduced half-life of ghrelin. Two enzymes involved in the deacylation of ghrelin have been identified: high-density lipoprotein-associated paraoxonase functions in the plasma, whereas lysophospholipase I, a thioesterase active against palmitoyl-Gs$\alpha$ and plamitoyl-coenzyme A, functions in the stomach (32–34). In contrast, the enzyme that catalyzes the acyl modification of ghrelin has not been identified.




FIG. 9. A, Effect of iv administration of ghrelin or des-acyl ghrelin (each at 1.5 nmol) on the plasma GH concentration in rats. *, $P < 0.001$ *vs.* preadministration; #, $P < 0.001$ *vs.* ghrelin at the same time point. B, Effect of ghrelin or des-acyl ghrelin administration (each at 200 pmol) on GH release from rat pituitary gland (n = 6 per group). *, $P < 0.001$ *vs.* control vehicle.

Acylation of ghrelin is essential for ghrelin's GH-releasing activity (1, 9, 10); several recent *in vitro* studies have shown that des-acyl ghrelin exhibits biological activities on the cell proliferation and metabolism of cardiomyocytes, adipocytes, myocytes, and myelocytes (18–22). Although many of these cells did not express the GHS-R, des-acyl ghrelin bound to their cell membranes (18–20). We here examined the orexigenic activity of des-acyl ghrelin. We confirmed the purity of ghrelin and des-acyl ghrelin by several biochemical methods before using these substances in feeding experiments. Both ghrelin and des-acyl ghrelin were completely pure by RP-HPLC, ion-exchange-HPLC, capillary zone electrophoresis, and mass spectrometry. Des-acyl ghrelin did not stimulate GH release when either peripherally administered to rats or applied directly to the rat pituitary *in vitro*. Intracerebroventricular administration of des-acyl ghrelin significantly induced feeding during both the light and dark phases in rats. Intracerebroventricular administration of des-acyl ghrelin also increased food intake in GHS-R-deficient mice and their wild-type littermates. Two recent studies reported the anorexic activity of des-acyl ghrelin in rats and mice (35, 36). In these studies, ip administration of des-acyl ghrelin suppressed feeding in rats had fasted for 16 h (35). Both ip and icv administrations of des-acyl ghrelin suppressed feeding in ddy mice that had been fasting for 16 h; icv administration of des-acyl ghrelin did not significantly change the light phase food intake in ddy mice fed *ad libitum* (36). These studies described that icv and ip administrations of des-acyl ghrelin expressed Fos in the PVN neurons, presumably corticotropin-releasing factor (CRF) neurons (35, 36). We also examined the effect of des-acyl ghrelin on feeding in ddy mice because the anorexic effect noted above contrasted the orexigenic effect observed in C57BL/6 mice. An icv administration of des-acyl ghrelin significantly increased the light phase food intake of ddy mice fed *ad libitum*. The icv administration of des-acyl ghrelin did not suppress food intake in ddy mice that had fasted for 16 h. In addition, an icv administration of des-acyl ghrelin did not express Fos in any neurons of the PVN where CRF-producing neurons are present. Because the effects of peptides in feeding experiments are hampered by unsatisfactory habituation (37, 38), all of the rats and mice used in these experiments were satisfactorily acclimated to handling before ip and icv injections. We do not know why our findings conflicted with previous results; des-acyl ghrelin, however, reproducibly stimulated feeding in rats, C57BL/6 mice and ddy mice. Des-acyl ghrelin, which was synthesized in the rat hypothalamus, was released in response to fasting (7). The ratio of des-acyl ghrelin to ghrelin in the rat hypothalamus was 2:1 under *ad libitum* conditions, and this ratio did not change in upon fasting. Des-acyl ghrelin, as well as ghrelin, may serve as orexigenic peptides in the hypothalamus.

Ghrelin-producing neurons localize to the hypothalamic arcuate nucleus and adjacent to the third ventricle between the dorsal, ventral, paraventricular, and arcuate hypothalamic nuclei of rats and mice (1, 24). Ghrelin fibers synapse on NPY/AgRP neurons in the arcuate nucleus and orexin neurons in the LHA (16, 24, 39). We investigated the signaling events downstream of des-acyl ghrelin that stimulates feeding. Fos expression, induced by icv administration of des-acyl ghrelin, was restricted to orexin-expressing neurons in the LHA. Des-acyl ghrelin-induced food intake was completely abolished in rats by pretreatment with antiorexin IgG, but not anti-NPY IgG or control serum IgG. Des-acyl ghrelin did not stimulate feeding in orexin-deficient mice. These results indicate that des-acyl ghrelin-induced feeding is mediated by the activation of the orexin pathway. Orexin-A and -B are hypothalamic peptides functioning in the regulation of feeding, energy homeostasis, and arousal (40). Approximately 3000 orexin-expressing neurons are present in the LHA of rats and mice. Orexin-positive nerve fibers have wide projections onto a variety of brain regions, such as the arousal centers in the forebrain and brain stem and the feeding center within the hypothalamus (40). Orexin-expressing neurons are heterogeneous in their anatomical projections and physiological functions, playing multifaceted roles in the brain. Ghrelin fibers project to orexin-positive neurons (16) and ghrelin stimulated elecrophysiological activity of isolated orexin neurons in the whole-cell patch-clamp study (41); we demonstrate here that ghrelin and des-acyl ghrelin acted on orexin-expressing neurons and that des-acyl ghrelin increased intracellular calcium concentration in isolated orexin neurons. There are three possible subtypes of orexin neurons: those that express the GHS-R as a receptor for ghrelin, those expressing an as-yet unknown target protein of des-acyl ghrelin, neurons possessing both proteins. Orexin also functions to maintain wakefulness (40). We examined the effect of des-acyl ghrelin on locomotor activity. As expected, icv administration of des-acyl ghrelin increased locomotor activity, suggesting that des-acyl ghrelin may increase wake-

fulness and locomotor activity for food seeking by stimulating orexin neurons.

We next investigated the functional relationship between des-acyl ghrelin and the GHS-R using GHS-R-deficient mice. The icv administration of des-acyl ghrelin to GHS-R-deficient mice induced food intake and Fos expression in orexin-expressing neurons. The icv administration of ghrelin to GHS-R-deficient mice did not stimulate food intake. Des-acyl ghrelin did not bind to GHS-R-expressing Chinese hamster ovary cells and did not inhibit the binding of ghrelin to rat pituitary culture cells expressing the GHS-R (1, 10, 42), implying that des-acyl ghrelin does not compete with ghrelin for the binding to the GHS-R. Thus, des-acyl ghrelin is thought to stimulate feeding via a mechanism independent of the GHS-R.

A number of gastrointestinal peptides transmit satiety or starvation signals to the nucleus of the solitary tract via the vagal afferents and/or to the hypothalamus via the bloodstream (43). Although iv administration of ghrelin stimulated both vagal afferents and feeding, iv administration of des-acyl ghrelin affected neither (44). Peripheral administration of des-acyl ghrelin to rats and mice did not affect feeding. Receptors on vagal afferents are generated by nodose ganglion neurons, transported to the nerve terminals through axonal transport (45). These results indicate that a receptor or a target protein binding to des-acyl ghrelin is not expressed in nodose ganglion neurons. The plasma concentration of des-acyl ghrelin increased upon fasting (7). The peripheral des-acyl ghrelin does not act to suppress feeding.

In summary, centrally administered des-acyl ghrelin increased feeding through activation of the orexin pathway. In addition to its peripheral actions, which include cell proliferation, inhibition of apoptosis, and fat metabolism (18–22), des-acyl ghrelin may function in hypothalamic feeding regulation. Central administration of des-acyl ghrelin to GHS-R-deficient mice stimulated feeding, suggesting that des-acyl ghrelin acts on a target protein that is specific for des-acyl ghrelin and independent of the GHS-R. Ghrelin and des-acyl ghrelin act in the regulations of peripheral cell functions through a common putative target protein (18–22). Ghrelin and des-acyl ghrelin function as orexigenic peptides in the hypothalamus. Des-acyl ghrelin may have basal effects of ghrelin-related peptides. Further studies examining the physiological and neuroanatomical interactions between des-acyl ghrelin and its target will establish roles of ghrelin peptides in the regulation of feeding and energy homeostasis.

## Acknowledgments

We thank Tomoko Tsuruta, Etsuko Masuda, and Ryusuke Koshida for assistance.

Received October 25, 2005. Accepted February 9, 2006.

Address all correspondence and requests for reprints to: Masamitsu Nakazato, M.D., Ph.D., Third Department of Internal Medicine, Miyazaki Medical College, Miyazaki University, Kiyotake, Miyazaki 889-1692, Japan. E-mail: nakazato@med.miyazaki-u.ac.jp.

This study was supported in part by grants from 21st Century Center of Excellence Program and grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology; the Ministry of Health, Labor, and Welfare; Novartis Foundation for Gerontological Research; Society of Molecular Mechanism of Digestive Tract; The Fujisawa Foundation; and Takeda Medical Research Foundation.

Disclosure summary: all authors have nothing to declare.

## References

1. **Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K** 1999 Ghrelin is a novel growth hormone releasing acylated peptide from stomach. Nature 402:656–660
2. **Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJS, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, Demartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LHT** 1996 A receptor in pituitary and hypothalamus that functions in growth hormone rrelease. Science 273:974–977
3. **MaKee KK, Palyha OC, Feighner SD, Hreniuk DL, Tan CP, Phillips MS, Smith RG, Van der Ploeg LHT, Howard AD** 1997 Molecular analysis of rat pituitary and hypothalamus growth hormone secretagogue receptors. Mol Endocrinol 11:415–423
4. **Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M** 2000 Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141: 4255–4261
5. **Dornonville de la Cour C, Björkqvist M, Sandvik AK, Bakke I, Zhao CM, Chen D, Håkanson R** 2001 A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control. Regul Pept 99:141–150
6. **Hosoda H, Kojima M, Matsuo H, Kangawa K** 2000 Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 281:1220–1225
7. **Sato T, Fukue Y, Teranishi H, Yoshida Y, Kojima M** 2005 Molecular forms of hypothalamic ghrelin and its regulation by fasting and 2-deoxy-D-glucose administration. Endocrinology 146:2510–2516
8. **Mondal MS, Date Y, Yamaguchi H, Toshinai K, Tsuruta T, Kangawa K, Nakazato M** 2005 Identification of ghrelin and its receptor in neurons of the rat arcuate nucleus. Regul Pept 126:55–59
9. **Kojima M, Kangawa K** 2005 Ghrelin: Structure and function. Physiol Rev 85:495–522
10. **Muccioli G, Tschöp M, Papotti M, Deghenghi R, Heiman M, Ghigo E** 2002 Neuroendocrine and peripheral activities of ghrelin: implication in metabolism and obesity. Eur J Pharmacol 440:235–254
11. **Matsumoto M, Hosoda H, Kitajima Y, Morozumi N. Minamitake Y, Tanaka S, Matsuo H, Kojima M, Hayashi Y, Kangawa K** 2001 Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun 287:142–146
12. **Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S** 2001 A role for ghrelin in the central regulation of feeding. Nature 409:194–198
13. **Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi, T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K** 2001 Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227–232
14. **Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I** 2001 Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 50: 2438–2443
15. **Bagnasco M, Tulipano G, Melis MR, Argiolas A, Cocchi D, Muller EE** 2003 Endogenous ghrelin is an orexigenic peptide acting in the arcuate nucleus in response to fasting. Regul Pept 111:161–167
16. **Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Shimbara T, Guan LL, Wand QP, Funahashi H, Sakurai T, Shioda S, Matsukura S, Kanagawa K, Nakazato M** 2003 Ghrelin-induced food intake is mediated via the orexin pathway. Endocrinology 144:1506–1512
17. **Sun Y, Wang P, Zheng H, Smith RG** 2003 Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 101:4679–4684
18. **Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A** 2004 Ghrelin and de-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159:1029–1037
19. **Cassoni P, Ghe C, Marrocco T, Tarabra E, Allia E, Catapano F, Deghenghi R, Ghigo E, Papotti M, Muccioli G** 2004 Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell line. Eur J Endocrinol 150:173–184
20. **Muccioli G, Pons N, Ghe C, Catapano F, Granata R, Ghigo E** 2004 Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol 498:27–35

21. **Bedendi I, Allatti G, Marcantoni A, Malan D, Catapano F, Ghe C, Deghenghi R, Ghigo E, and Muccioli G** 2003 Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol 476: 87–95
22. **Thompson NM, Gill DAS, Davies R, Loveridge N, Houston PA, Robinson ICAF, Wells T** 2004 Ghrelin and des-octanoyl ghrelin promote adipogenesis directly *in vivo* by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145:234–242
23. **Fraley GS, Ritter S** 2003 Immunolesion of norepinephrine and epinephrine afferents to medial hypothalamus alters basal and 2-deoxy-D-glucose-induced neuropeptide Y and agouti gene-related protein messenger ribonucleic acid expression in the arcuate nucleus. Endocrinology 144:75–83
24. **Cowley MA, Smith RG, Diano S, Tschöp M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nillni EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD, Horvath TL** 2003 The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37:649–661
25. **Sagar SM, Sharp FR, Curran T** 1988 Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240:1328–1331
26. **Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M** 1999 Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437–451
27. **Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangawa K, Sakurai T, Yanagisawa M, Nakazato M** 1999 Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci USA 96:748–753
28. **Paxinos G, Watson C** 1998 The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press
29. **Nishi Y, Hiejima H, Hirohara M, Sato T, Kangawa K, Kojima M** 2005 Developmental changes in the pattern of ghrelin's acyl modification and the levels of acyl-modified ghrelin in murine stomach. Endocrinology 146:2709–2715
30. **Akamizu T, Shinomiya T, Irako T, Fukunaga M, Nakai Y, Nakai Y, Kangawa K** 2005 Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J Clin Endocrinol Metab 90:6–9
31. **Akamizu T, Takaya K, Irako T, Hosoda H, Teramukai S, Matsuyama A, Tada H, Miura K, Shimizu A, Fukushima M, Yokode M, Tanaka K, Kangawa K** 2004 Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 150:447–455
32. **Beaumont NJ, Skinner VO, Tan TM, Ramesh BS, Byrne DJ, MacColl GS, Keen JN, Bouloux PM, Mikhailidis DP, Bruck-dorfer KR, Vanderpump MP, Srai KS** 2003 Ghrelin can bind to a species of high density lipoprotein associated with paraxonase. J Biol Chem 278:8877–8880
33. **Shanado Y, Kometani M, Uchiyama H, Koizumi S, Teno N** 2004 Lysophospholipase I identified as a ghrelin deacylation enzyme in rat stomach. Biochem Biophys Res Commun 325:1487–1494
34. **Duncan JA, Gilman AG** 1998 A cytoplasmic acyl-protein thioesterase that removes plamitate from G protein $\alpha$ subunits and p21(RAS). J Biol Cehm 273:15830–15837
35. **Chen CY, Imui A, Asakawa A, Fujino K, Kato I, Chen CC, Ueno N, Fujimiya M** 2005 Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology 129:8–25
36. **Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, Kasuga M** 2005 Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54:18–24
37. **Tschöp M, Castaneda TR, Joost HG, Thone-Reineke C, Ortmann S, Klaus S, Hagan MM, Chandler PC, Oswald KD, Benoit SC, Seeley RJ, Kinzig KP, Moran TH, Beck-sickinger AG, Koglin N, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Schindler M, Arndt K, Rudolf K, Mark M, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Craney S, Flora D, Smiley D, Heiman ML** 2004 Physiology: does gut hormone PYY3–36 decrease food intake in rodents? Nature 430:1–4
38. **Halatchev IG, Ellacott KL, Fan W, Cone RD** 2004 Peptide YY3–36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145:2585–2590
39. **Jobst EE, Enriori PJ, Cowley MA** 2004 The electrophysiology of feeding circuits. Trends Endocrinol Metab 15:488–499
40. **Sakurai T** 2005 Reverse pharmacology of orexin: from an orphan GPCR to integrative physiology. Regul Pept 126:3–10
41. **Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, Tominaga M, Yagami K, Sugiyama F, Goto K, Yanagisawa M, Sakurai T** 2003 Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 38:701–713
42. **Muccioli G, Papotti M, Locatelli V, Ghigo E, Deghenghi R** 2000 Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest 24:RC7–RC9
43. **Konturek SJ, Konturek JW, Pawlik T, Brzozowski T** 2004 Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol 55:137–154
44. **Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M** 2002 The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion. Gastroenterology 123:1120–1128
45. **Date Y, Toshinai K, Koda S, Miyazato M, Shimbara T, Tsuruta T, Niijima A, Kangawa K, Nakazato M** 2005 Peripheral interaction of ghrelin and cholecystokinin on feeding regulation. Endocrinology 146:3518–3525

***Endocrinology* is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.**

0013-7227/06/$15.00/0
*Printed in U.S.A.*

Endocrinology 147(3):1333–1342
Copyright © 2006 by The Endocrine Society
doi: 10.1210/en.2005-0708

# Maternal Ghrelin Plays an Important Role in Rat Fetal Development during Pregnancy

Keiko Nakahara, Mari Nakagawa, Yukiko Baba, Miho Sato, Koji Toshinai, Yukari Date, Masamitsu Nakazato, Masayasu Kojima, Mikiya Miyazato, Hiroyuki Kaiya, Hiroshi Hosoda, Kenji Kangawa, and Noboru Murakami

*Department of Veterinary Physiology (K.N., M.Nakag., Y.B., M.S., N.M.), Faculty of Agriculture, University of Miyazaki, Miyazaki 889-2155, Japan; Third Department of Internal Medicine (K.T., Y.D., M.Nakaz.), Miyazaki Medical College, Kiyotake, Miyazaki 889-1692, Japan; Molecular Genetics (M.K.), Institute of Life Science, Kurume University, Kurume 839-0864, Japan; and National Cardiovascular Center Research Institute (M.M., H.K., H.H., K.K.), Osaka 565-8565, Japan*

**Ghrelin, an acylated peptide serving as an endogenous ligand for GH secretagogue receptor (GHS-R), was originally isolated from rat and human stomach. In this study, we report the critical role of maternal ghrelin in fetal development. High levels of ghrelin receptor (GHS-R) mRNA were detected in various peripheral fetal tissues beginning at embryonic d 14 and lasting until birth. Fetal GHS-R expression was also confirmed in fetal tissues by immunohistochemistry. Autoradiography revealed that both des-acyl ghrelin and acyl ghrelin bind to fetal tissues. Chronic treatment of mothers with ghrelin resulted in a significant increase in birth weight in comparison to newborns from saline-treated mothers. Even when maternal food intake after ghrelin treatment was restricted through paired feeding, significant stimulation of fetal development still occurred. Conversely, active immunization of mothers against ghrelin decreased fetal body weight during pregnancy. A single ghrelin injection into the mother increased circulating ghrelin levels in the fetus within 5 min of injection, suggesting that maternal ghrelin transits easily to the fetal circulation. High levels of des-acyl ghrelin were detected in fetal blood and amniotic fluid. Both acylated and des-acyl ghrelin increased [$^3$H]thymidine and 5-bromo-2′-deoxyuridine incorporation of cultured fetal skin cells in a dose-dependent manner, and calcium-imaging analysis revealed that acyl and des-acyl ghrelin increased the $Ca^{2+}$ influx in discrete cultured fetal skin cells, respectively. These results indicate that maternal ghrelin regulates fetal development during the late stages of pregnancy. (*Endocrinology* 147: 1333–1342, 2006)**

GHRELIN, RECENTLY purified from rat and human stomachs as an endogenous ligand for the GH secretagogue receptor (GHS-R), is a 28-amino acid peptide with an *n*-octanoylation modification at Ser[3] (1). This octanoylation is important for the stimulation of GH secretion from the pituitary gland (1). Although cells immunostained for ghrelin are distributed widely in the stomach, hypothalamus, pituitary gland, liver, kidney, pancreas, and placenta, the main source of circulating ghrelin is considered to be the gastrointestinal tract (2–6). Both acylated and des-acyl ghrelin are observed in the peripheral circulation, the levels of des-acyl ghrelin being higher (7, 8). Several studies on the physiological function of ghrelin have demonstrated that, in addition to stimulating GH secretion, ghrelin also stimulates food intake and body weight gain independent of GH secretion (8–13). It is likely that the appetite-stimulating effect of peripheral ghrelin is due to action via the afferent vagal nerve (14). In contrast, the central effect is thought to be via neuropeptide Y and agouti-related peptide secretion from the arcuate nucleus in the hypothalamus (11, 15). Administration of ghrelin continuously to rodents resulted in fat deposition and obesity (9). These effects of ghrelin on appetite and fat deposition are counteracted by leptin (11). These results imply that ghrelin may play an important role in the regulation of food intake and energy expenditure.

The ghrelin receptor GHS-R, highly conserved from teleost fish to humans, is expressed widely in both central and peripheral organs, including the brain, pituitary gland, and pancreas (16–19). The broad distribution of GHS-R suggests that ghrelin may play important roles in addition to those mentioned above. It has been also demonstrated that ghrelin might be involved in stomach motility (10), gastric acid secretion (20), insulin and gastrin release (21), the cardiovascular system, and stress reactions (12). In addition, we demonstrated previously that neonatal rats treated daily with ghrelin for 2 or 3 wk from birth showed faster eye and vaginal opening than those of saline-treated group (22), suggesting that ghrelin may be involved in neonatal development. Therefore, it has been assumed that ghrelin from the maternal stomach or placenta during pregnancy may play a role in fetal development. In the present study, we examined the possible involvement of maternal ghrelin in rat fetal development.

## Materials and Methods

### *Animals*

Wistar rats were housed under controlled temperature (23 ± 1 C) and regulated 12-h light 12-h dark conditions (lights on at 0700 h). Female rats were mated on the day of proestrus at approximately 3 months old.

**First Published Online December 8, 2005**

Abbreviations: BrdU, 5-Bromo-2′-deoxyuridine; E, embryonic day; GHS-R, GH secretagogue receptor; mcKLH, mariculture keyhole limpet hemocyanin.

***Endocrinology* is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.**

The next estrus day was considered to be d 0 of pregnancy. As reported previously, delivery usually occurs in our rat colony during the morning on d 21 of pregnancy (23). The average number (±SEM) of pups per mother at delivery was 13.10 ± 1.78 (n = 122). All procedures were performed in accordance with the Japanese Physiological Society's guidelines for animal care.

### *RT-PCR for GHS-R 1a mRNA*

Total RNA was extracted from fetal tissues on d 14, 15, and 19 of pregnancy using Trizol reagent (Invitrogen, Carlsbad, CA) as described previously (24). First-strand cDNA was synthesized from 2 μg of total RNA by random primer RT. The resulting cDNA was subjected to PCR amplification using sense and antisense primers specific for GHS-R1a (24). PCR products were electrophoresed on a 2% agarose gel. GAPDH was used as a control housekeeping gene.

### *Autoradiography for [$^{125}$I]acyl ghrelin*

Fetuses [embryonic d 17 (E17)] were embedded in Tissue-Tec OCT compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan) and frozen. Sections cut using a cryostat were mounted on gelatin-coated glass slides. Autoradiography was performed as described previously (14) with the following minor modifications. After preincubation for 30 min in incubation buffer at room temperature, sections were incubated for 12 h at 4 C in buffer containing 20 ng/ml rat [$^{125}$I-Tyr$^{29}$]acylated rat ghrelin. Nonspecific binding was determined in the presence of excess unlabeled acyl or des-acyl rat ghrelin (10 μg/ml). Sections were then exposed to an IP plate (Fuji Film, Tokyo, Japan) for 12 h and analyzed on BAS-5000 (Fuji Film).

### *Preparation of anti-GHS-R serum*

The [Cys$^0$]-rat GHS-R [342–364] peptide was synthesized using the Fmoc solid-phase method on a peptide synthesizer (433A; Applied Biosystems, Foster City, CA), then purified by reverse phase-HPLC. The synthesized peptide (10 mg) was conjugated to maleimide-activated mariculture keyhole limpet hemocyanin (6 mg) (mcKLH; Pierce, Rockford, IL) in conjugation buffer (Pierce). The conjugate was emulsified with an equal volume of Freund's complete adjuvant and was used to immunize New Zealand white rabbits by intracutaneous and sc injection. Animals were boosted every 2 wk and bled 7 d after each injection. The specificity of the antisera was confirmed by the immunoreactivity of GHS-R-expressing cells (CHO-GHSR62 cells) and lack thereof in control cells.

### *Immunohistochemistry for GHS-R*

Immunohistochemical analyses for GHS-R were performed on frozen fetuses (E17 and 19) using a modification of a method that has been described previously (25). The fetuses were placed in fixative for 5 d at 4 C and then transferred to 0.1 M phosphate buffer containing 20% sucrose. They were cut into serial, 12-μm-thick sections at −20 C with a cryostat. The sections were incubated for 2 d with a rabbit-anti-GHS-R antibody at 4 C. Slides were then incubated with Alexa-546-labeled goat-antirabbit IgG antibody (Molecular Probes, Inc., Eugene, OR; dilution 1:400). Samples were observed with the aid of an Olympus AX-70 fluorescence microscope (Olympus, Tokyo, Japan). To examine the specificity of GHS-R antibody in tissue sections, the reaction was also performed using GHS-R antibody that had been preabsorbed with excess synthetic GHS-R (10 μg).

### *Measurement of acyl and des-acyl ghrelin, IGF-I, and corticosterone*

Levels of acyl or des-acyl ghrelin were measured by specific ELISA kits for acyl or des-acyl ghrelin (Mitsubishi Kagaku Iatron, Inc., Tokyo, Japan). The ELISA can detect each acyl or des-acyl ghrelin using two specific antibodies recognizing only acyl ghrelin (octanoylation modification at [Ser$^3$]-ghrelin [1–11]) or only des-acyl ghrelin (nonoctanoylation modification at [Ser$^3$]-ghrelin [1–11]). Blood collected from pregnant rats and their fetuses was immediately put into chilled polypropylene tubes containing a protease inhibitor, aprotinin (Sigma-Aldrich, St. Louis, MO), and 2Na-EDTA and then centrifuged. We then added a 10% plasma volume of 0.1 N HCl. Maternal blood was taken at 0830 h (satiety phase) at 2-d intervals from d 11–21. Fetal blood and amniotic fluid were collected on d 17, 19, and 21.

To examine the transit of maternal acyl ghrelin to the fetal circulation, acyl ghrelin (0.2 and 20 nmol) or saline was injected into pregnant rats iv under light ether anesthesia on d 19 of pregnancy (n = 12 per group). Blood was then collected from both the mother and fetus at 5, 10, and 30 min after injection.

To determine the effect of maternal treatment with acyl ghrelin on plasma IGF-I and corticosterone levels in the fetal circulation, fetal plasma IGF-I and corticosterone levels were measured by enzyme immunoassay kit (Funakoshi, Tokyo, Japan) and [$^{125}$I]corticosterone RIA kit (ICN Biomedicals, Costa Mesa, CA), respectively. The limit of assay sensitivity was 5 ng/ml for IGF-I and 20 ng/ml for corticosterone. The intra and interassay coefficients of variation were 5 and 16%, respectively, for IGF-I, and 6 and 12%, respectively, for corticosterone.

### *Ghrelin administration and neonatal body weights*

We sc injected either saline, acyl ghrelin (1.5 or 3.0 nmol), or des-acyl ghrelin (3.0 nmol) three times a day (at 0830, 1330, and 1830 h) from d 14 to delivery, or continuously infused vehicle, acyl ghrelin (0.125 or 0.5 nmol/h) or des-acyl ghrelin (0.5 nmol/h) through an osmotic minipump implanted sc from d 15 until delivery (n = 10 per group) (11, 26). We also injected 3 nmol acyl ghrelin three times a day from d 14 to delivery into pair-fed pregnant rats and the effect was compared with saline-treated pregnant rats. Neonatal body weights were measured on the day of delivery. If the pups numbered more than 15 or less than 11 they were excluded from the analyses.

### *Passive immunization for acyl ghrelin*

Rat acyl ghrelin (3 mg) was conjugated to a carrier protein, mcKLH (3 mg), in conjugation buffer (Pierce) (7). Each conjugate was emulsified with an equal volume of Freund's adjuvant. Immunization, initiated by intradermal injection in 44-d-old female rats, was repeated six times at 2-wk intervals. As a control antigen, carrier protein alone without ghrelin was administered. Rats were mated on d 114 after the fifth immunization. The antibody titers were verified in diluted plasma every 10 d after immunization using [$^{125}$I]ghrelin binding capacity.

### *Quantitative RT-PCR of GH mRNA in fetal pituitary*

The pituitary gland and blood were collected from E19 and E20 fetuses, isolated from the mothers' implanted osmotic minipump (acyl ghrelin 0.5 nmol/h and saline). GH mRNA expression was measured by real-time quantitative PCR as described previously (25). Experiments contrasted the relative levels of both GH and GAPDH transcripts in every sample. The total RNA from each tissue was extracted using an RNeasy Micro kit (Qiagen, Valencia, CA) and synthesized into first-strand cDNA using an iScript cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA). An aliquot of the first-strand cDNA (40–100 ng tissue equivalent) was quantified on an iCycler (Bio-Rad Laboratory) using iQ SYBR Green Supermix (Bio-Rad Laboratory) with primers to amplify GAPDH (25) and GH specifically (26).

### *Incorporation of [$^3$H]thymidine or 5-bromo-2′-deoxyuridine (BrdU) into cultured cells*

We assessed the effect of acyl and des-acyl ghrelin administration on the proliferation of fetal skin cells by measuring the incorporation of [$^3$H]thymidine (2 μCi/ml) or BrdU (10 μM). Dispersed fetal skin cells were prepared from E17 fetuses by sequential collagenase treatment, papain digestion, and mechanical desegregation. Dispersed cells were then suspended in MCDB15$^3$HAA medium (F-Peptide Co., Ltd., Yamagata, Japan) containing 2% fetal calf serum, penicillin (100 U/ml), streptomycin (100 μg/ml), and 5 ng/ml epidermal growth factor. Cells were seeded in polyethylenimine-coated 48- and 96-well dishes at densities of $5 \times 10^5$ per well and $3 \times 10^4$ per well for the [$^3$H]thymidine and BrdU experiments, respectively. BrdU was detected using a Cell Proliferation ELISA Kit (Roche Diagnostic GmbH, Mannheim, Germany), as reported by Kusunoki *et al.* (27).

### Statistics

Values are given as means ± SEM. Comparisons between two groups were made by ANOVA with the *post hoc* Fisher test. Differences at $P < 0.05$ were accepted as statistically significant.

## Results

### Expression of GHS-Rs in fetal tissue

GHS-R1a mRNA expression was detected in various fetal tissues with a high density in the spinal cord from E14 until birth (Fig. 1A). GHS-R mRNA expression in the fetal pituitary was also detected at E19. To confirm the expression of GHS-R in fetal tissues at the protein level, we performed immunohistochemistry on E17 fetuses using an antibody specific for GHS-R. Positive cells were distributed extensively in fetal tissues; the skin, bone, intestine, tongue, and muscle being stained particularly strongly (Fig. 1, C–G). Immunoreactivity was not detected in sections that were incubated with GHS-R antiserum that had been preabsorbed with excess synthetic GHS-R (Fig. 1, D-2 and F-2). Although RT-PCR analysis demonstrated the expression of GHS-R mRNA in sections of the brain, pituitary, stomach, and lung, only relatively weak staining was observed in these organs.




FIG. 1. A, GHS-R 1a mRNA expression in various fetal tissues. Fetal (E14, 15, 19) tissue cDNA fragments were amplified by PCR in the presence of oligonucleotide primers specific for GHS-R 1a. B, Sagittal section of E17 fetuses immunostained for GHS-R by avidin-biotin-peroxidase complexes (Vectastain Elite ABC Kit; Vector Laboratories, Burlingame, CA) using a diaminobenzidine substrate kit (Vector Laboratories). C–G, Immunofluorescence staining for GHS-R in fetal ribs (C), tongue (D), intestine (E), skin (F), and the muscle between the two transverse processes of a thoracic vertebra (G). D-2 and F-2 represent the immunostaining using absorbed antiserum with excess of synthetic GHS-R. *Bar* scales are: 3.7 mm (B); 75 μm (C); 65 μm (D); 75 μm (E); 100 μm (F); 75 μm (G). H–J, [$^{125}$I]acyl ghrelin autoradiograph of a sagittally sectioned fetus (E17) (H). Replacement was examined in the presence of excess unlabeled acyl (I) or des-acyl (J) ghrelin. The *red color* indicates the highest binding state with [$^{125}$I]acyl ghrelin (high binding order: *red* > *yellow* > *green* > *blue colors*).

[125I]Acyl ghrelin autoradiography revealed dense binding to bone, skin, heart, and tongue (Fig. 1H); similar to the immunohistochemistry, the brain and digestive tract bound the isotope only weakly. In addition, excess unlabeled acyl ghrelin (Fig. 1I) and des-acyl ghrelin (Fig. 1J) could displace with [125I]acyl ghrelin binding. More potent replacement was observed in excess unlabeled des-acyl ghrelin treatment (Fig. 1J).

*Circulating ghrelin levels during late pregnancy*

We measured the circulating levels of acyl and des-acyl ghrelin in pregnant rats and their fetuses, respectively. The levels of acyl ghrelin in maternal plasma exhibited a gradual but not significant decline in late pregnancy (Fig. 2A). In contrast, des-acyl ghrelin increased significantly during late pregnancy (Fig. 2A). Both ghrelin forms, acyl and des-acyl ghrelin, were also present in the fetal circulation; these levels decreased gradually as the time for delivery approached (Fig. 2B). We noticed a significant difference in des-acyl ghrelin levels when compared between the maternal and fetal plasma: the fetal levels of des-acyl ghrelin were 5- to 10-fold higher than the maternal levels (Fig. 2, A and B). On d 17 and 19 of pregnancy, we detected a large quantity of des-acyl ghrelin in the amniotic fluid (Fig. 2C). Acyl ghrelin levels increased rapidly in fetal blood within 5 min of administration of either 0.2 or 20 nmol acyl ghrelin (iv) into the mother (Fig. 2D). In the case of the 20-nmol dose, although maternal trunk ghrelin levels declined 30 min after injection, fetal trunk ghrelin levels were still increased at the sampling time.




FIG. 2. A, Plasma acyl and des-acyl ghrelin levels in pregnant rats during late pregnancy. B, Fetal plasma levels of acyl and des-acyl ghrelin. C, Acyl and des-acyl ghrelin levels in amniotic fluid. All *black and white bars* represent the levels of acyl and des-acyl ghrelin, respectively. Each *bar* and *vertical line* represent the mean ± SEM (n = 8). *Asterisks* indicate significant differences (A, $P < 0.05$ *vs.* E11; B, $P < 0.05$ *vs.* E17). D, Maternal and fetal levels of circulating acyl ghrelin after iv injection of saline or 0.2 and 20 nmol acyl ghrelin into mothers at d 19 of pregnancy. The *right and left vertical scales* correspond to 0.2 and 20 nmol acyl ghrelin treatments, respectively.

### *Effect of chronic ghrelin treatment on fetal body weight at birth*

We examined the effect of prolonged maternal treatment with ghrelin, beginning at d 14 or 15 of pregnancy and lasting until delivery, on neonatal body weight at birth. Chronic treatment with acyl ghrelin, either by injection three times per day (Fig. 3A) or constant infusion through an osmotic mini-pump (Fig. 3B), significantly increased the average neonatal body weight at birth in comparison to that of neonates delivered by a saline-treated group. We observed more than a 10% body weight gain, and the increase was dose-dependent. No significant changes were observed after treatment with des-acyl ghrelin.

We investigated the effect of acyl ghrelin injection on food intake of pregnant females. Daily treatment with acyl ghrelin significantly increased daily maternal food intake (Fig. 3C). However, a paired feeding study demonstrated that even when pregnant females treated with acyl ghrelin consumed the same amount of food as saline-treated pregnant females, neonatal body weight was significantly greater in the ghrelin-treated group (Fig. 3D).

To examine the effect of endogenous maternal ghrelin on fetal development, we compared the birth weight of pups born to mothers passive-immunized against a complex of acyl ghrelin and mcKLH (carrier protein) with that of pups born to mothers passive-immunized against mcKLH. After six immunizations at 2-wk intervals beginning at 44 d after birth, rats were mated when the relative ghrelin binding titer was maximally increased (Fig. 3E). Although body weight gain was temporarily lower, it was not significantly so. The body weights of ghrelin-immunized females recovered gradually to normal levels at 104 d of age (Fig. 3E). The body weights of neonates born to mothers passive-immunized against acyl ghrelin were lower than those of neonates born to saline-treated mothers (Fig. 3F).

### *Effect of ghrelin on GH mRNA levels in fetal pituitary tissue, and IGF-I and corticosterone levels in fetal plasma*

If GH, prolactin, or corticosterone secretions from fetal pituitary or adrenal tissues were stimulated by maternal ghrelin, the released hormone might stimulate fetal development. We examined the effect on fetal pituitary GH mRNA levels and fetal plasma IGF-I or corticosterone levels by administering acyl ghrelin to pregnant females. However, pituitary GH mRNA at E19 and E20 was not affected by this treatment (Fig. 4A). In addition, fetal plasma IGF-I and corticosterone concentrations at E19 and E20 were not affected by maternal ghrelin treatment (Fig. 4, B and C). We found no significant change in fetal prolactin levels (data not shown).

### *Effect of ghrelin on proliferation of cultured fetal skin cells*

To examine a possibility of direct effect of circulating ghrelin on fetal development, we examined the fetal cell proliferation by ghrelin using [$^{3}$H]thymidine and BrdU incorporation. We used primary cultured fetal skin cells at E17, because abundant cells at this stage were easy to collect. Both [$^{3}$H]thymidine (Fig. 5A) and BrdU (Fig. 5, B–E) incorporation increased significantly after treatment with acyl ghrelin in a dose-dependent or time-dependent manner. Des-acyl ghrelin was more potent than acyl ghrelin at stimulating the proliferation of fetal skin cells (Fig. 5E). The GHS-R antagonist [D-Lys$^{3}$]-GHRP-6 inhibited acyl ghrelin- and des-acyl ghrelin-stimulated cell proliferation (Fig. 5E).

Calcium-imaging analysis revealed two types of fetal skin cells (Fig. 5F): one type responding to des-acyl ghrelin, but not to acyl ghrelin, and the other responding to acyl ghrelin, but not to des-acyl ghrelin. No. 21 and 23 cells were shown as examples, respectively.

## Discussion

The present study clearly demonstrated that maternal ghrelin would play an important role in fetal development during pregnancy; first, exogenous chronic treatment of the mother with ghrelin increased fetal body weight at birth; second, mothers immunized against ghrelin delivered fetuses with a lower body weight; and third, proliferation of cultured fetal skin cells was stimulated by ghrelin. Both GHS-R1a mRNA expression and GHS-R protein were detected in various fetal tissues. Autoradiography using [$^{125}$I]acyl ghrelin also demonstrated dense binding to the bone, skin, heart, and tongue. This distribution of functional GHS-R throughout peripheral fetal tissues suggests that ghrelin acts on such fetal peripheral tissues. Surprisingly, excess unlabeled des-acyl ghrelin could displace completely with [$^{125}$I]acyl ghrelin binding, suggesting that the acyl modification is dispensable for ghrelin function in binding site of fetal tissues. Because des-acyl ghrelin does not bind to GHS-R (1), we presume that fetal tissues may express a GHS-R subtype for des-acyl ghrelin. In support of this supposition (28, 29), it has been shown that the increases in plasma glucose and decreases in insulin, but not increases in GH secretion, induced by acyl ghrelin administration can be counteracted by coadministration of des-acyl ghrelin (28). In addition, ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and phosphatidylinositol 3-kinase/AKTJ (30).

Plasma total ghrelin levels have been measured in pregnant women, rats, and human fetuses (31–34). In pregnant rats, plasma total ghrelin, determined with an antibody recognizing the C-terminal region, was shown to decrease at around the middle to late stage of pregnancy (31). Total ghrelin increases at around mid-gestation in human pregnancy (32, 33). Human fetuses exhibit levels of total ghrelin in umbilical venous blood that are not correlated with either gestational age or maternal ghrelin levels (34). In addition, ghrelin mRNA expression has been observed in the placenta and ovary of pregnant rats, and in the fetal pancreas (3, 35, 36). It has also been reported that ghrelin might play an important role in the regulation of blood pressure and the development of preimplantation embryos (37, 38). In the present study, both acyl and des-acyl ghrelin were present in the maternal and fetal circulations during the last half of pregnancy, and there was a significant difference in des-acyl ghrelin levels between the maternal and fetal plasma. The fetal levels of plasma des-acyl ghrelin were 5- to 10-fold higher than the maternal levels. In addition, we detected a large quantity of des-acyl ghrelin in the amniotic fluid. As




FIG. 3. A and B, Effect on neonatal body weight at birth of daily sc injections of ghrelin (A) or continuous infusion of ghrelin with an osmotic minipump (B) into pregnant rats. Treatment with ghrelin was performed from d 14 until delivery. C, Daily food intake in pregnant rats (A) and in pair-fed pregnant rats treated with acyl ghrelin on the same schedule as A. D, The effect of daily sc injection of 3 nmol acyl ghrelin into pair-fed pregnant rats on neonatal body weight at birth. Acyl ghrelin was injected three times daily from d 14 until delivery. Paired feeding for the saline-treated group also begun on d 15 of pregnancy. E, Comparison of body weight and relative antibody titer between rats immunized against ghrelin-mcKLH complex (●, ■) or carrier protein alone (○, □). The relative titer (●, ○) was expressed as a dilution rate at 50% binding capacity. Each *bar* (A–E) and *symbol* (F) and *vertical line* represent the mean ± SEM. The *upper numbers* represent the total number of newborn rats compared in each group. *Asterisks* indicate significant differences ($P < 0.05$ *vs.* control). F, Comparison of the body weight of newborn rats delivered from rats passive-immunized with the ghrelin-mcKLH complex or with carrier protein alone (mcKLH).

demonstrated previously, ghrelin-positive cells were not evident in the fetal stomach until E19 by immunohistochemistry using an antibody recognizing the N-terminal of acyl ghrelin, suggesting that fetal plasma ghrelin originates from the maternal placenta and/or the maternal blood (3, 22). Indeed, acyl ghrelin levels in fetal plasma increased rapidly




FIG. 4. A, The effect of continuous infusion of acyl ghrelin into pregnant rats on fetal pituitary GH mRNA levels (A) and fetal plasma IGF-I (B) and corticosterone levels (C). Acyl ghrelin was infused at a rate of 0.5 nmol per hour with an osmotic minipump beginning on d 14 and lasting until delivery. The fetal pituitary and plasma were collected at E19 and E20. Each *bar and vertical line* represent the mean ± SEM (n = 6).

within 5 min after administration of acyl ghrelin to the mother, indicating that maternal ghrelin easily transits to the fetal circulation. Although maternal trunk ghrelin levels declined 30 min after injection, fetal trunk ghrelin increased at the time, probably resulting from a longer half-life of ghrelin in fetuses than in adults, and high levels of des-acyl ghrelin might accumulate in the fetal circulation. The existence of GHS-R and an additional GHS-R subtype in fetal tissues, combined with both acyl ghrelin and large quantities of des-acyl ghrelin in the fetal circulation and amniotic fluid, supports the hypothesis that maternal ghrelin plays a critical role in fetal development.

Fetal growth is mainly influenced by the nutrition provided by the mother through the arteria umbilicalis (39, 40). Decreases in the amount of food given to pregnant mothers during the gestational period tend to decrease the size of their neonatal pups in comparison with pups born to mothers fed *ad libitum*. Daily treatment with acyl ghrelin significantly increased daily maternal food intake. The stimulation of fetal growth by maternal ghrelin injection would result from increased nutrition provided by the mother. However, a paired feeding study demonstrated that even when pregnant females treated with acyl ghrelin consumed the same amount of food as saline-treated pregnant females, neonatal body weight was significantly greater in the ghrelin-treated group. This result indicates that maternal ghrelin affected fetal development through a mechanism independent of increased nutrition.

In rats, a rapid increase in fetal body weight occurs during the last quarter of pregnancy. The somatotroph, a GH-secreting cell, appears in the fetal pituitary near E18 (41). Pituitary GH mRNA at E19 and E20 was not altered by ghrelin treatment, indicating that maternal ghrelin-induced fetal development is not due to increased release of fetal GH. The stimulation of maternal GH secretion by daily treatment of ghrelin, leading to the transition of maternal GH to fetal circulation, may stimulate fetal development. Garcia-Aragon and colleagues (42) provided evidence for the wide distribution of GH receptor in the mid-late gestation of rat fetus. The receptor expression markedly increased between E12 and E18; the receptor was present in all major organ systems at E18. Genetically manipulated model mice, Laron dwarfs, with inactivating GH receptor mutations, were shorter in length than normal at birth. Congenitally GH-deficient newborn babies are also much shorter (43, 44). In contrast, the fetuses of GH-deficient dwarf rats were proportionately smaller in size (45). However, we previously reported that continuous infusion of ghrelin to rats stimulated GH secretion for several days, but that the effect decreased after prolonged administration (26). Levels of GH mRNA within the pituitary were also decreased by these treatments (26), probably due to transcriptional down-regulation. In addition, fetal plasma IGF-I levels were not affected by maternal treatment with ghrelin. We found no significant change in fetal circulating levels of corticosterone and prolactin during maternal ghrelin administration. Therefore, the stimulation of fetal development by maternal ghrelin administration is probably not due to the maternal GH and fetal circulating IGF-I and corticosterone levels.

Both [$^3$H]thymidine and BrdU incorporation increased significantly after treatment with acyl ghrelin in a dose-dependent and time-dependent manner. Interestingly, des-acyl ghrelin stimulated proliferation more potently than acyl ghrelin. The GHS-R antagonist [D-Lys$^3$]-GHRP-6 inhibited